Depo-Provera Lawsuit 2025 | Brain Tumor Claims, Eligibility & Settlement Updates

The Depo Provera lawsuit in 2025 has grown as more women come forward with claims that the birth control injection caused serious health problems, including meningioma brain tumors and long-term bone loss. Many users say they were not properly warned about these risks and are now seeking answers and compensation. The litigation is moving through important stages in federal court as judges review scientific evidence and legal arguments that will shape future outcomes. This page gives a clear overview of the claims being filed, who may qualify, expected settlement trends, and what to watch as the case continues to develop.

What the Depo-Provera Lawsuit Is About

The Depo Provera lawsuit centers on claims that Pfizer did not properly warn women about the serious health risks linked to the birth control injection. Many lawsuits say that long-term use of the shot is connected to meningioma, which is a type of brain tumor. Women argue that research has shown this risk for many years, yet the company did not give clear warnings that would have helped them make safer decisions. Some patients developed tumors that required surgery, scans, and ongoing medical care, and they are now asking for compensation for their medical costs, pain, and long-term harm.

Pfizer says it tried to update the label with a warning, but the FDA did not approve the change. The plaintiffs respond that the company still had a responsibility to clearly communicate known risks. This disagreement is a major issue in the ongoing litigation.

Timeline of Depo-Provera Litigation

The timeline of the Depo Provera litigation shows how the lawsuit has developed over the years, highlighting key updates, court actions, and major events that continue to shape the direction of the case.

September 30, 2025 – Major Arguments Presented on the Preemption Issue

A significant hearing took place in the Depo Provera litigation as Judge Rodgers reviewed Pfizer’s attempt to win summary judgment. Pfizer argued that federal oversight blocks the failure to warn claims, while plaintiffs countered that the company did not provide the regulator with essential information, making the defense unreliable. The judge pressed both sides with questions but did not signal how she may rule. Despite the uncertainty, the plaintiffs left the courtroom confident that the preemption argument is unlikely to end the federal cases. A separate ninety-minute case management session was also held, though it produced no meaningful updates.

September 22, 2025 – Plaintiffs Challenge Pfizer’s Preemption Argument

The women pursuing claims over Depo-Provera-related brain tumours filed an extensive legal response challenging Pfizer’s attempt to have the lawsuits thrown out on preemption grounds. They argue that Pfizer never provided the FDA with complete information about the meningioma risk, including important study data and scientific evidence that was shared more fully with regulators in other countries.

The filing also explains that the FDA never issued a final rejection of a stronger warning, and Pfizer’s decision to withdraw lower dose versions while resubmitting updated materials shows that clearer labeling was possible. Plaintiffs maintain that federal rules did not stop Pfizer from offering safer options or more specific risk disclosures. Their position is that Pfizer cannot meet the strict standard required to prove impossibility, and they believe the preemption defense should not succeed.

September 11, 2025 – Case Count Ticks Higher

There are now over 800 Depo-Provera lawsuits pending in the MDL, a significant jump from roughly 550 cases the previous month. The rapid increase reflects growing awareness of the alleged link between Depo-Provera and meningioma, as well as rising confidence among plaintiffs following recent filings and court activity.

September 8, 2025 – Kaiser Named as a Defendant

A new lawsuit filed in Alameda County Superior Court alleges that a California woman developed multiple intracranial meningiomas after nearly a decade of Depo-Provera use administered through Kaiser facilities. She first experienced symptoms such as vertigo and double vision in 2020 and later required surgical removal of one tumor, while others remain under lifelong monitoring. The complaint also brings claims against the Kaiser entities, asserting that they promoted Depo-Provera as a safe product even though they knew or should have known about the tumour risks and that they presented their safety information as if it had been independently evaluated.

September 3, 2025: New Cleveland Clinic Study

A major Cleveland Clinic study published in JAMA Neurology has reshaped the Depo Provera litigation landscape. Analyzing data from more than ten million women across sixty-eight health systems, researchers found that long-term users, especially those who began after age 31 or used the drug for more than four years, face a significantly increased risk of intracranial meningioma. The study reports a relative risk of 2.43 compared to non-users, while all other contraceptives showed no measurable danger.

Although not as dramatic as the Roland findings, the results are strong and suitable for Daubert. The real-world impact is substantial: roughly one additional tumor for every 1,100 exposed women, which translates into thousands of preventable tumors given the drug’s widespread use. The study eliminates the defense argument that no United States population data existed and strengthens the position that Pfizer failed to warn despite safer alternatives.

September 2, 2025: Preemption Motion

Pfizer has advanced a new preemption argument in the Depo Provera MDL, claiming the FDA blocked the company from adding a meningioma warning after a 2024 submission. According to Pfizer, the FDA issued a complete response letter nine months later, rejecting the proposed label change, which the company now frames as a federal barrier to state law failure to warn claims. Plaintiffs counter that Pfizer long possessed evidence linking synthetic progestins to meningiomas and delayed action for decades.

They argue that Pfizer could have strengthened the warning through the CBE process and that the FDA never prohibited a clinically meaningful risk-based warning. Plaintiffs view Pfizer’s preemption strategy as an attempt to avoid discovery and recast years of inaction as a regulatory constraint. If accepted, the motion could eliminate both warning and design defect claims, but plaintiffs say it ignores Pfizer’s long history of delay and under-disclosure.

August 22, 2025 – Judge Seeks Clarity on Unfiled Claims

Judge M. Casey Rodgers has ordered lead plaintiffs’ firms to disclose how many Depo Provera claims they are holding without filing. She warned that firms that wait to file until after a ruling on preemption could jeopardize their leadership roles in the MDL. Her concern is practical. Unfiled inventories make it difficult for the court to gauge the size of the litigation, coordinate scheduling, and prepare for settlement or trial.

This issue has surfaced before in mass torts. The AFFF litigation saw confusion and pushback when defendants grew alarmed by hidden inventories. Other MDLs have shown that filing too many cases too early can also create problems, as seen in Zantac when thousands of registry claims were wiped out by broad Daubert and preemption rulings. Plaintiffs’ lawyers are trying to avoid repeating that outcome.

Attorneys are not holding cases without reason. Their priority is to safeguard clients while avoiding premature filings that could be harmed by procedural maneuvers. A claims registry remains the most balanced solution. It would give the court full visibility, protect plaintiffs from unnecessary exposure, and prevent firms from being penalized for acting prudently in a developing MDL.

August 23, 2025 – Preemption Becomes the Central Battleground

Federal preemption has become the main issue in the Depo Provera MDL. Pfizer is arguing that the FDA’s 2024 refusal to approve a proposed label change blocks state-law failure to warn claims. If the court accepts this position, many cases could end before full discovery begins. The legal test is demanding. Pfizer has to demonstrate that the FDA explicitly turned down the precise warning the plaintiffs argue was required, rather than a vague or more general proposal. Plaintiffs will maintain that the company still had the ability to strengthen the warning using the CBE process and that the FDA never ruled out a direct, risk-based disclosure.

The situation is comparable to offering a minimal warning and then blaming the regulator when the language is deemed inadequate. Pfizer’s proposal in 2024 used vague wording that lacked scientific clarity. The agency declined it, which is not the same as refusing a more precise warning that accurately reflected the data. Pfizer is now trying to treat that rejection as a legal shield. Preemption was never intended to protect companies that make weak attempts to warn and then stop trying.

August 16, 2025 – Dispute Over Attorneys’ Fees and Court Authority

A recent motion challenges the reach of the court’s Amended Common Benefit Order No. 1. The order labels any attorney with one MDL case as Participating Counsel and claims the right to withhold fees from cases both inside and outside the MDL. The motion argues that the court cannot extend fee holdbacks to unrelated state or unfiled cases because those plaintiffs have received no common benefit and never agreed to contribute.

This debate centers on how common benefit funds operate. Such funds compensate lawyers who perform work that advances all plaintiffs’ interests, but fee contributions are only allowed when a settlement creates a common pool or when attorneys agree to participate. Without those conditions, the court cannot divert fees from clients who are not part of the MDL’s structure. Conflicts like this appear often in large coordinated litigations. They highlight the balance courts must strike between efficiency and fairness when determining how to compensate leadership counsel without overreaching into cases beyond their authority.

August 12, 2025 – Large Group of Plaintiffs Files in Delaware

A new lawsuit filed in Delaware state court has added one hundred more plaintiffs to the expanding group of Depo Provera cases outside the federal MDL. Although the MDL remains the main hub for coordinated federal proceedings, more plaintiffs are choosing Delaware and other states to pursue separate actions that follow their own schedules and may offer procedural advantages.

August 2, 2025 – Steady Growth in Federal and State Filings

The MDL has now reached 550 filed cases, confirming its role as the center of the litigation. State court activity is also increasing, although the numbers remain smaller. California has eleven cases awaiting coordination, while New York leads with sixty-one filings waiting for assignment. Additional claims are appearing in states such as Pennsylvania, Illinois, New Mexico, and Delaware.

This spread across multiple jurisdictions benefits plaintiffs. Each state court operates with its own procedures and deadlines, which forces Pfizer to respond on several fronts at the same time. That variability creates pressure, since an early state court trial could occur before any MDL bellwether, shaping settlement expectations for the entire litigation.

July 25, 2025 – Questions Surround the 150 mg Depo Provera Dose

Depo Provera is given as a 150 mg intramuscular shot that sends a large amount of synthetic progestin into the body for several months. Plaintiffs are now asking whether such a high dose was ever truly necessary, especially since lower dose options like Depo SubQ Provera 104 provide the same contraceptive protection with far less medication. The lawsuits suggest that the larger dose may have increased the likelihood of intracranial meningiomas. Discovery will explore whether Pfizer ever reconsidered the dose as new research emerged, or whether the 150 mg strength remained out of routine or commercial reasons. If safer alternatives were available and ignored, jurors may decide that this decision placed patients at avoidable risk.

July 18, 2025 – State Court Activity Continues to Expand

State filings are increasing, although they remain smaller in number compared to the MDL, which now includes about 550 cases. California currently has eleven cases waiting for coordination, and New York holds the largest state total with sixty-one awaiting assignment. Additional suits are appearing in Pennsylvania, Illinois, New Mexico, and Delaware. This broad distribution signals a growing secondary track of litigation that may heighten pressure on Pfizer as the federal cases progress.

July 2, 2025 – Texas Family Files Wrongful Death Claim

A new wrongful death lawsuit has been filed in the MDL by the family of a Texas woman who passed away from what was found to be a hemorrhage caused by an undiagnosed intracranial meningioma. The complaint states that she used Depo Provera for many years, including during her time in Minnesota between 2006 and 2012. She died suddenly at age forty-seven in October 2024. Her family alleges that long-term exposure to the contraceptive injection triggered the tumor that ultimately led to her death.

June 16, 2025 – Philadelphia Effort Fades as Cases Shift Elsewhere

Plans for a coordinated Depo Provera mass tort in the Philadelphia Court of Common Pleas have stalled. After a judge separated nearly all one hundred plaintiffs from a combined case and allowed them to refile individually, none of the separated plaintiffs submitted new filings. Pfizer also withdrew its request for coordination. Only a single case remains on the docket, leaving Philadelphia with little activity for now.

Momentum has instead moved to the federal MDL in the Northern District of Florida, which has more than four hundred active cases, along with additional lawsuits appearing in state courts across the country. Those venues are currently driving the direction of the litigation.

June 8, 2025 – Multiple States Begin Building Active Depo Provera Dockets

Cases are now being filed in multiple state courts, creating a growing network of parallel actions that sit alongside the federal MDL. This trend has been anticipated for some time and is now clearly taking shape. In California, six matters are awaiting coordination, and defendants have formally asked the Judicial Council to organise the proceedings. The Council has, in turn, requested that the Presiding Judge in Alameda County propose both a coordination judge and an appropriate venue.

New York is emerging as the most active state forum, with sixty cases on the docket. A unified proceeding there appears imminent. The Litigation Coordinating Panel has placed fifty-eight of those actions on hold while it considers consolidation and has set a mid-June deadline for any objections. None are expected, as the plaintiffs support the move. Both sides have agreed to rely on BrownGreer Centrality for case administration, signalling a shared interest in streamlined management.

Additional filings are appearing elsewhere. Pennsylvania now has three cases, including a mass complaint involving one hundred claimants. Individual actions are also pending in Illinois, New Mexico, and Delaware. The tally for Illinois does not include the Daniels matter, which has already been shifted to the MDL.

Collaboration between the parties is improving in major jurisdictions such as California and New York, reducing redundant discovery and limiting avoidable disputes. These coordinated state venues are likely to play an influential role in the direction and strategy of the broader litigation.

May 13, 2025 – Projected Number of Depo-Provera Lawsuits

Roughly two to three million people in the United States receive Depo-Provera injections each year. Meningioma occurs at a background rate of about 9.5 cases per 100,000 annually, which would equate to roughly 190 to 285 cases within this population. When the reported 5.5-fold elevation in risk is applied, the projected number increases to approximately 1,045 to 1,568 cases each year. Only a portion of affected individuals ever bring a lawsuit, and past mass-tort patterns suggest that somewhere between five and twenty percent of those who may have been harmed ultimately pursue legal action.

May 12, 2025 – Evidence Required to Participate in Depo Shot MDL

Judge Rodgers released Pretrial Order No. 22, which explains the process for addressing gaps or problems in plaintiffs’ Proof of Use and Proof of Injury materials. Every claimant is required to complete a Use and Injury Questionnaire and upload the necessary records through the BrownGreer MDL Centrality platform. The order makes clear that plaintiffs must provide documentation confirming that they were given an eligible Depo-Provera product and that they were diagnosed with a qualified meningioma.

May 6, 2025 – Meningioma Study Backs Up Roland Study

A new University of British Columbia study has given plaintiffs additional scientific support. In a nested case-control analysis of more than 319,000 contraceptive users, Depo-Provera use for more than one year was associated with a 3.55-fold increased risk of intracranial meningioma. The study corrected key flaws in the earlier Roland research by using a larger sample, adding an active comparator, and applying lag periods to account for tumor latency. These stronger methods make the findings harder for defendants to challenge and bolster the argument that Pfizer failed to warn about known risks.

March 31, 2025: Proof of Product Use

Demonstrating actual Depo Provera use has become a key requirement in the case. Plaintiffs are obligated to submit a Proof of Use and Injury Questionnaire within 120 days of 14 March 2025, or within 120 days of filing if their lawsuit was brought at a later date. To support this, the court has ordered pharmacies, clinics, hospitals, insurers, and military medical providers to release records confirming whether plaintiffs received Depo Provera or a generic DMPA injection, even when individual medical records are missing. Institutions often retain purchase logs, shipping records, and insurance data that can identify which product was used. The order authorizes HIPAA and HITECH-compliant release forms and allows subpoenas when necessary, preventing facilities from imposing extra red tape, proprietary forms, or unreasonable fees.

January 28, 2025: Is It All About the Money?

While anticipated Depo Provera settlement amounts are discussed below, these cases are not only about financial recovery. Mass tort litigation serves a broader purpose by holding drug manufacturers accountable and protecting future patients. But in civil law, compensation is the only remedy available, and no apology from Pfizer will undo the harm. For victims, the goal is straightforward: securing the maximum settlement possible. So yes, money matters, but so does justice.

December 7, 2024: New Lawsuit in Pennsylvania State Court

The Philadelphia Depo Provera docket continues to expand as anticipated. Another lawsuit has been submitted in the Philadelphia Court of Common Pleas by a local woman who says long-term use of the Depo Provera injection led to a severe meningioma. She began receiving the contraceptive as a teenager and argues that Pfizer and the other manufacturers did not provide adequate warnings about the dangers linked to medroxyprogesterone acetate, the drug’s active ingredient. According to the complaint, she required several brain operations and now lives with ongoing physical and cognitive difficulties. She is seeking both compensatory and punitive damages.

October 31, 2024: European Warning

Pfizer has updated the Depo Provera label in the European Union and the United Kingdom, along with possible revisions in other regions. The EU label now contains added language under Special warnings and precautions for use that states:

“Meningioma: Meningiomas have been reported following long term administration of progestogens, including medroxyprogesterone acetate. Depo Provera should be discontinued if a meningioma is diagnosed. Caution is advised when recommending Depo Provera to patients with a history of meningioma.”

Plaintiffs’ attorneys will continue to highlight the optics of Pfizer issuing warnings overseas while providing no comparable warning in the United States. Even this updated language is limited. It frames the risk vaguely, suggests only general caution, and advises discontinuation only after a tumor is diagnosed. It does not meaningfully warn about the potential for Depo Provera to cause meningioma in patients without a prior history. Plaintiffs’ lawyers argue that a stronger, clearer warning is needed everywhere and that a watered-down statement in the United States would not constitute a real warning at all.

October 8, 2024: Depo Provera Lawsuit Statute of Limitations

Many women ask whether they are running out of time to file a Depo Provera claim, yet most current cases should not face statute of limitations barriers. Two legal doctrines offer significant protection. One is the discovery rule, which postpones the filing deadline until a person becomes aware, or reasonably should become aware, of both the injury and its link to the product.

In these meningioma cases, it would have been unrealistic for patients to recognise the connection before newer scientific research brought the risk to light. The second doctrine is fraudulent concealment, which allows plaintiffs to assert that the manufacturers deliberately failed to disclose the dangers tied to extended use of the drug. When considered together, these principles provide strong support for the position that most claims are still within the permitted timeframe.

October 6, 2024: Depo Provera Lawsuits in Philadelphia

An increasing share of Depo Provera claims from across the United States is being brought in Pennsylvania state courts, particularly in Philadelphia. The Philadelphia Court of Common Pleas is widely regarded for its experienced judges and its Complex Litigation Center, which has extensive experience handling large pharmaceutical and product liability dockets.

Plaintiffs are able to file in this forum because Viatris Inc., one of the defendants, is based in Pennsylvania, which permits cases from any state to be heard there. The state’s procedures also offer several advantages, including flexible rules for grouping related cases and evidentiary standards that are often viewed as more accommodating to plaintiffs. Philadelphia juries have a reputation for taking claims of corporate misconduct seriously and for listening closely to individuals who allege injury. This reputation can influence settlement discussions. For all of these reasons, the litigation is expected to progress both in the federal MDL and through coordinated state proceedings, with Philadelphia remaining a key location in the overall landscape.

September 25, 2024: Could a Class-Action Suit Be Filed Over Depo Provera?

Many women are asking whether the Depo Provera litigation will become a class action lawsuit, but that outcome is unlikely. The most probable path is the creation of a federal MDL. A class action is not the best structure for compensating women in this litigation because it treats all plaintiffs the same, regardless of the severity of their individual injuries. In a class action, there is usually one trial or one settlement, and the compensation is divided among all participants in the same way, which does not work for a case involving a wide range of harm.

An MDL offers a better structure. In an MDL, cases are consolidated only for pretrial purposes. Each plaintiff keeps her own lawsuit, and her injuries, medical history, and damages are evaluated individually. If a global settlement does not occur, cases can move forward to trial on their own. This approach is more appropriate for Depo Provera claims, where the nature and severity of injuries vary significantly.

There is also the possibility of state MDLs. When many cases are filed within a single state, those courts can group them before one judge for coordinated pretrial proceedings. State MDLs function similarly to the federal process but remain entirely within state courts. This could occur in states such as Ohio, Pennsylvania, and New York, where Depo Provera corporate defendants are located and can be sued. In large pharmaceutical litigations like this one, it is common to see both state and federal MDLs progressing at the same time, each working toward either a global settlement or individual trials.

Health Risks & Injuries Linked to Depo-Provera (Brain Tumors, Bone Loss, etc.)

Many women who used Depo Provera for birth control have reported serious health problems after long-term use. The drug is now under legal scrutiny because several studies and patient experiences suggest it may cause significant and sometimes permanent harm. Below is an introduction to the main health risks and injuries connected to Depo Provera.

Health risks linked to Depo Provera include:

• A higher chance of developing meningioma, which is a brain tumor that can cause headaches, vision problems, seizures, memory issues, and other neurological symptoms.
• Loss of bone mineral density, especially in the spine and hips. This can lead to weaker bones, osteoporosis, and a greater risk of fractures later in life.
• Bone loss that may not fully recover even after stopping the injections.
• Mood changes such as depression, anxiety, or emotional instability.
• Seizures or convulsions in some users.
• Eye and vision problems, including migraines or double vision.
• Blood clots may form in the legs, lungs, or other parts of the body.
• A possible increase in certain cancer risks based on some research.
• Liver-related problems or changes in liver function.
• Delayed return to fertility, with some women needing many months before becoming pregnant after stopping the shots.

These reported injuries are central to the growing number of lawsuits filed by women who believe they were not properly warned about the dangers of long-term Depo Provera use.

Who Can Join the Depo-Provera Lawsuit & How to File?

People may be able to join the Depo Provera lawsuit if they used the birth control injection and later developed serious health problems that are believed to be linked to the drug. Most cases involve women who developed meningioma brain tumors after long-term use. Others may qualify if they experienced severe bone loss or other significant injuries that required medical treatment. In general, a person must show that they used Depo Provera for an extended period, suffered a diagnosed injury, and that their condition can reasonably be connected to the drug.

Filing a claim usually starts with a free case review from a law firm that handles product liability or dangerous drug cases. A lawyer will ask for details such as medical records, the length of Depo Provera use, and any diagnoses or surgeries. If the case qualifies, the attorney prepares the paperwork, files the claim in the appropriate court, and guides the person through the legal process. There is no need to file alone because lawyers handle the investigation, evidence gathering, and communication with the court.

Settlement Status & Compensation Outlook for Depo-Provera Claims

The Depo Provera lawsuit is still in progress, and there is no global settlement at this time. The cases are being handled together in federal court, and lawyers are still gathering evidence and preparing for early test trials. These trials will help show how strong the claims are and often influence how much future settlements may be worth. The legal process is still in the early stages, so no payouts have been offered yet.

Many law firms expect that any future settlement will depend on how severe each person’s injuries are. People who developed meningioma but did not need major surgery may fall into a lower compensation range. Those who had surgery, ongoing symptoms, or long-term medical problems may fall into a higher range. The most serious cases, such as multiple tumors or lasting neurological issues, could receive the highest compensation.

These estimates are only predictions. The final settlement amounts will depend on medical proof, the outcome of the first trials, how much harm a person suffered, their medical expenses, and how strongly their condition is linked to Depo Provera. For now, the compensation outlook remains uncertain until the early trials and major legal rulings take place.

Legal Arguments, Court Decisions & What They Mean for the Lawsuit

The Depo Provera lawsuit is shaped by several important legal arguments that both sides continue to fight over. One of the main disputes is whether Pfizer properly warned women about the risk of meningioma and other serious injuries. The plaintiffs argue that the company knew or should have known about the danger and failed to update the warning label in a timely and clear way. They also claim the drug was sold without giving doctors enough information to help patients understand the long-term risks.

Pfizer argues that it cannot be held responsible under many state laws because the Food and Drug Administration controls drug labels. The company says it tried to add stronger warnings, but the agency did not approve those changes. This argument is called preemption, and it is one of the biggest issues in the case. If a court agrees with Pfizer, many claims could be limited. If a court rejects the argument, the lawsuit will move forward with fewer barriers.

Early court decisions have mostly focused on how to handle evidence, which studies can be used, and what the judge wants from both sides as they prepare for trial. The courts have allowed the litigation to proceed, which signals that the claims have enough support to be heard. Judges have also ordered detailed schedules for discovery, evidence sharing, and expert reports, showing that the case is being prepared for bellwether trials. These test trials will help determine how strong the evidence is and how juries may respond.

What these legal rulings mean is that the lawsuit is moving forward, but key decisions still lie ahead. The outcome of the preemption arguments will have a major impact on how many claims survive. The results of the first trials will likely shape settlement amounts and the overall direction of the litigation. For now, the case remains active and continues to build momentum as both sides prepare for the next steps.

What’s Next in the Depo-Provera Litigation?

The Depo Provera litigation is moving into a more active phase as courts and lawyers prepare for the next major steps. The biggest focus now is the upcoming decisions on the preemption issue. This ruling will determine whether Pfizer can avoid many state law claims by arguing that the FDA controls drug label changes. The judge’s decision on this point will shape the future of the entire case.

Another important step is the continued exchange of evidence. Both sides are gathering medical studies, company documents, and expert opinions. This stage will help clarify how strong the scientific link is between Depo Provera and injuries like meningioma and bone loss. The court will soon review expert testimony to decide what information can be presented at trial.

Once these steps are complete, the court will select and schedule bellwether trials. These early test trials will show how juries respond to the evidence and how convincing the arguments are on each side. Their outcomes often influence settlement discussions and may help push the parties toward negotiations.

Overall, the next phase of the Depo Provera litigation involves key rulings, more evidence development, and the preparation for the first trials. These actions will set the direction of the lawsuit and help determine how strong the claims are and what future compensation may look like.

Frequently Asked Questions (FAQs) About Depo-Provera Lawsuits